AndhraNews.net
Home » Business News » 2014 » April » April 22, 2014

Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014


April 22, 2014 - London

ORION CORPORATION   STOCK EXCHANGE RELEASE 22 APRIL 2014 at 10:45 A.M. EEST

Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014

Orion will publish its Interim Report for January-March 2014 on Tuesday, 29 April 2014 approximately at 12:00 Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en/investors promptly after the publishing.

News conference for analysts and media on Tuesday 29 April 2014 at 13:30 EEST

A news conference for analysts and media will be held on Tuesday 29 April 2014 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.

Live webcast and conference call

The event can be followed live as a webcast accessible at http://qsb.webcast.fi/o/orion/orion_2014_0429_q1.

Questions can be asked also through conference call lines after the result presentation. The conference call ID is 943080 and the phone numbers to participate the conference are:

when calling from the United States           +1 334 323 6201
when calling from other countries              +44 (0)20 7162 0025

News conference recordings

A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

Orion Corporation

Timo Lappalainen
President and CEO
Jari Karlson
CFO

Publisher:
Orion Corporation
www.orion.fi/en

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

HUG#1778560

GlobeNewswire

Comment on this story

Share